Molecule Information

General Information of the Molecule (ID: Mol04200)

• Name: ATPase ,Homo sapiens
• Synonyms: ATPase
• Molecule Type: Protein

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Drug

Investigative Drug(s) 1 drug(s) in total

Formononetin

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Disease Class: multidrug resistance cancer [ICD-11: 2D4Z] [1]

• Sensitive Disease: multidrug resistance cancer [ICD-11: 2D4Z]
• Sensitive Drug: Formononetin
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: ABCB1/Flp-InTM-293 cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: P-gp ATPase assay
• Experiment for Drug Resistance: SRB assay
• Mechanism Description: This study demonstrated the finding of a natural product, formononetin, which is a potent inhibitor of human P-gp via uncompetitive inhibition and ATPase stimulation. Formononetin resensitized MDR cancer cells to chemotherapeutic drugs.

Disease Class: multidrug resistance cancer [ICD-11: 2D4Z] [1]

• Sensitive Disease: multidrug resistance cancer [ICD-11: 2D4Z]
• Sensitive Drug: Formononetin
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Zebrafish xenograft model; Zebrafish
• Experiment for Molecule Alteration: P-gp ATPase assay
• Experiment for Drug Resistance: Zebrafish xenograft assay
• Mechanism Description: This study demonstrated the finding of a natural product, formononetin, which is a potent inhibitor of human P-gp via uncompetitive inhibition and ATPase stimulation. Formononetin resensitized MDR cancer cells to chemotherapeutic drugs.

References

• Ref 1: Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein. Int J Mol Sci. 2024 Aug 2;25(15):8471.